Expression of the BCR-ABL oncogene is the founding genetic lesion and the cytogenetic hallmark of both Ph+ ALL and chronic myeloid leukemia (CML) [131,132]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.